Catalyst Pharmaceuticals (CPRX) Earnings Analysis
Catalyst Pharmaceuticals (CPRX) has no confirmed upcoming earnings date. Last quarter (2026-05-11) it missed with EPS 0.52 USD vs 0.64 USD est (-18.8%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E 17.49.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CPRX next report earnings?
No confirmed upcoming earnings date is currently scheduled for CPRX. This page updates as the calendar is published.
CPRX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | 0.52 USD | 0.64 USD | -18.8% | Miss |
| 2025-02-26 | 0.7 USD | 0.32 USD | +118.7% | Beat |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
CPRX valuation and analyst view
| Trailing P/E | 17.49 |
|---|---|
| Trailing EPS | 1.81 USD |
| Price / book | 3.80 |
| Dividend yield | 0.00% |
| Market cap | 3.85B |
| Analyst consensus | Buy (12 buy / 4 hold / 0 sell) |
| Avg price target | 31.75 USD |
Related research pages
Frequently asked questions
When is Catalyst Pharmaceuticals (CPRX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for CPRX. This page updates as the calendar is published.
Did CPRX beat earnings last quarter?
In its 2026-05-11 report, CPRX posted EPS of 0.52 USD versus a 0.64 USD estimate — a miss of 18.8%.
What is CPRX's earnings track record?
Over the last 2 reported quarters with consensus data, CPRX beat estimates 1 times (50%).
What is CPRX's current P/E ratio and EPS?
CPRX trades at a trailing P/E of 17.49 on trailing EPS of 1.8103513212649407 USD.
What do analysts rate CPRX?
Analyst consensus is "Buy" across 16 ratings (0 strong buy, 12 buy, 4 hold, 0 sell, 0 strong sell). Average 12-month price target: 31.75 USD.